Management of Merkel Cell Carcinoma
Surgery with wide local excision (1-2 cm margins to fascia) is the primary treatment for localized Merkel cell carcinoma, combined with sentinel lymph node biopsy for staging in clinically node-negative patients, followed by adjuvant radiation therapy to reduce locoregional recurrence. 1
Initial Diagnostic Approach
Perform excisional biopsy of the entire lesion with narrow margins to obtain accurate histopathologic diagnosis and microstaging before definitive treatment 2. This is critical because wide local excision performed first can interfere with the accuracy of subsequent sentinel lymph node mapping, particularly for head, neck, and trunk lesions 2.
Diagnostic Workup
- Immunohistochemistry panel: CK-20 (positive in MCC), TTF-1 (negative in MCC, positive in small cell lung cancer), plus chromogranin A, synaptophysin, and neurofilament 1
- Imaging: PET/CT is preferred for staging with 90% sensitivity and 98% specificity; it changes stage and treatment in 22% of cases and identifies bone metastases missed by CT alone 1
- CT or MRI if PET/CT unavailable 1
Surgical Management Algorithm
For Clinically Localized Disease (N0, M0)
Wide local excision: 1-2 cm margins to the investing fascial layer 1
- Alternative: Mohs micrographic surgery or complete circumferential peripheral and deep-margin assessment (CCPDMA) when tissue sparing is critical (e.g., facial lesions) 1
- Critical caveat: If using Mohs, send a specimen from the central tumor portion for permanent section microstaging 1
- Do not delay adjuvant radiation to achieve wider margins—margin status has no impact on locoregional failure when adjuvant radiation is given 1
Sentinel lymph node biopsy (SLNB): Perform routinely in all clinically node-negative patients who are otherwise healthy 2
If SLNB positive: Proceed with completion lymph node dissection and/or radiation therapy 2
Reconstruction Considerations
- Verify clear margins before major reconstruction 1
- Minimize delay to adjuvant radiation through primary closure when possible 1
- Avoid significant tissue movement that obscures the radiation target area 1
Adjuvant Radiation Therapy
Postoperative radiation therapy reduces local and regional recurrence risk and is associated with prolonged time to recurrence and improved survival 2. The panel recommends radiation as a treatment option for all stages of MCC 2.
- Meta-analysis data show that adjuvant radiation after complete excision lowers both local and regional recurrence rates 2
- Radiation should be administered to the primary site and/or regional lymph nodes based on risk 2
Systemic Therapy
For Stage IV Metastatic Disease (M1)
- Chemotherapy regimens (though data insufficient for survival benefit) 2:
- Etoposide + cisplatin or carboplatin
- Cyclophosphamide + doxorubicin + vincristine
- Topotecan (for older patients)
For Regional Disease (N+)
- Most institutions reserve chemotherapy for metastatic disease 2
- A few institutions consider adjuvant chemotherapy for selected N+ cases, though retrospective data do not show prolonged survival benefit 2
Emerging Therapies
- Checkpoint immunotherapy (anti-PD-1/PD-L1) has shown benefit in advanced disease and is being evaluated in resected disease 3, 4, 5
Follow-Up Schedule
Intensive surveillance is essential as median time to recurrence is 8 months, with 90% of recurrences occurring within 24 months 2:
- Year 1: Complete skin and regional lymph node examination every 1-3 months
- Year 2: Every 3-6 months
- Year 3+: Annually
This schedule applies regardless of N0, N+, or M1 status 2. Patient self-examination is important as MCC patients have increased risk for other non-melanoma skin cancers 2.
Key Pitfalls to Avoid
- Do not perform wide local excision before SLNB—this interferes with lymphatic mapping accuracy 2
- Do not delay adjuvant radiation to achieve wider surgical margins—margin status doesn't affect outcomes when radiation is given 1
- Do not skip SLNB based on tumor size—positive sentinel node incidence is independent of primary tumor size 2
- Do not rely solely on clinical nodal examination—SLNB is the most sensitive staging test for nodal metastases 1
Multidisciplinary Approach
A multidisciplinary panel is recommended to ensure coordinated care for this rare and aggressive disease 1, 6. This should include surgical oncology, radiation oncology, medical oncology, and dermatopathology expertise.